Cargando…
Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products
BACKGROUND AND OBJECTIVES: In 2010, an intravenous immunoglobulin (IVIG) product was removed from the market due to an association with serious thromboembolic events. Investigations revealed that factor XIa (FXIa) was present as a process‐related impurity. This study investigated the ability of two...
Autores principales: | Wilmot, Helen V., Gray, Elaine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359487/ https://www.ncbi.nlm.nih.gov/pubmed/33277936 http://dx.doi.org/10.1111/vox.13046 |
Ejemplares similares
-
Establishment of the World Health Organization 2(nd) International Standard for Factor XI, Plasma, Human
por: Wilmot, Helen, et al.
Publicado: (2017) -
ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study
por: Beale, Dominic, et al.
Publicado: (2021) -
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022) -
Production of $\Xi_{c}^{0}$ and $\Xi_{b}$ in Z decays and lifetime measurement of $\Xi_{b}$
por: Abdallah, J., et al.
Publicado: (2005) -
Production of Xi_c^0 and Xi_b in Z decays and lifetime measurement of Xi_b
por: Berntzon, Lisa
Publicado: (2005)